# US 2026/0085131 A1 · Bispecific antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085131 A1
- Document ID: US20260085131A1
- Status: Published application
- Kind: A1
- Application number: 19/304,720
- Filed: 2025-08-20
- Published: 2026-03-26
- Earliest claimed: 2017-08-01
- Assignees: Therapeutics, Inc.
- Applicants: Ab Therapeutics, Inc.
- Inventors: Yue Liu; Wenyan Cai; Jiadong Shi
- Web page: https://patentgrep.com/patent/US20260085131A1

## CPC

- C07K 16/2887: {against CD20}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/567: Framework region [FR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.

## Claims

### Claim 1

A bispecific antibody or antigen-binding fragment thereof comprising
a first heavy chain variable region,
a second heavy chain variable region,
a first light chain variable region, and
a second light chain variable region,
wherein the first heavy chain variable region and the first light chain variable region associate with each other, forming a first antigen binding region that specifically binds to a first antigen with a binding affinity greater than 107 M−1, 108 M−1, 109 M−1, 1010 M−1, 1011 M−1, or 1012 M−1, and
the second heavy chain variable region and the second light chain variable region associate with each other, forming a second antigen binding region that specifically binds to a second antigen with a binding affinity less than 109 M−1, 108 M−1, 107 M−1, 106 M−1, 105 M−1, or 104 M−1.

### Claim 2 (depends on 1)

The bispecific antibody or antigen-binding fragment thereof of claim 1, wherein the second antigen binding region specifically binds to the second antigen with a binding affinity greater than 107 M−1, 106 M−1, 105 M−1, or 104 M−1.

### Claim 3 (depends on 1)

The bispecific antibody or antigen-binding fragment thereof of claim 1, wherein the binding affinity of the first antigen binding region when it binds to the first antigen is at least 100, 1000, or 10000 times greater than the binding affinity of the second antigen binding region when it binds to the second antigen.

### Claim 4 (depends on 1)

The bispecific antibody or antigen-binding fragment thereof of claim 1, wherein the first light chain variable region and the second light chain variable region are at least 90%, 95%, 99%, or 100% identical.

### Claim 5

A bispecific antibody or antigen-binding fragment thereof comprising a first arm comprising a first heavy chain variable region, and a first light chain variable region; and
a second arm comprising a second heavy chain variable region, and a second light chain variable region,
wherein the first arm specifically binds to a first antigen with a binding affinity greater than 107 M−1, 108 M−1, 109 M−1, 1010 M−1, 1011 M−1, 1012 M−1, and the second arm specifically binds to a second antigen with a binding affinity less than 109 M−1, 108 M−1, 107 M−1, 106 M−1, 105 M−1, or 104 M−1.

### Claim 6 (depends on 5)

The bispecific antibody or antigen-binding fragment thereof of claim 5, wherein the second arm specifically binds to the second antigen with a binding affinity greater than 107 M−1, 106 M−1, 105 M−1, or 104 M−1.

### Claim 7 (depends on 5)

The bispecific antibody or antigen-binding fragment thereof of claim 5, wherein the binding affinity of the first arm when it binds to the first antigen is at least 100, 1000, or 10000 times greater than the binding affinity of the second arm when it binds to the second antigen.

### Claim 8 (depends on 5)

The bispecific antibody or antigen-binding fragment thereof of claim 5, wherein the first light chain variable region and the second light chain variable region are at least 90%, 95%, 99%, or 100% identical.

### Claim 9

A bispecific antibody or antigen-binding fragment thereof comprising
a first heavy chain comprising a first heavy chain variable region,
a second heavy chain comprising a second heavy chain variable region,
a first light chain comprising a first light chain variable region, and
a second light chain comprising a second light chain variable region,
wherein the first heavy chain variable region and the first light chain variable region associate with each other, forming a first antigen binding region that specifically binds to a first antigen with a binding affinity greater than 107 M−1, 108 M−1, 109 M−1, 1010 M−1, 1011 M−1, 1012 M−1, and
the second heavy chain variable region and the second light chain variable region associate with each other, forming a second antigen binding region that specifically binds to a second antigen with a binding affinity less than 109 M−1, 108 M−1, 107 M−1, 106 M−1, 105 M−1, or 104 M−1.

### Claim 10 (depends on 9)

The bispecific antibody or antigen-binding fragment thereof of claim 9, wherein the second antigen binding region specifically binds to the second antigen with a binding affinity greater than 107 M−1, 106 M−1, 105 M−1, or 104 M−1.

### Claim 11 (depends on 9)

The bispecific antibody or antigen-binding fragment thereof of claim 9, wherein the binding affinity of the first antigen binding region when it binds to the first antigen is at least 100, 1000, or 10000 times greater than the binding affinity of the second antigen binding region when it binds to the second antigen.

### Claim 12 (depends on 9)

The bispecific antibody or antigen-binding fragment thereof of claim 9, wherein the first light chain and the second light chain are at least 90%, 95%, 99%, or 100% identical.

### Claim 13 (depends on 9)

The bispecific antibody or antigen-binding fragment thereof of claim 9, wherein the first heavy chain and the second chain associate with each other by the knobs into holes approach.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The bispecific antibody or antigen-binding fragment thereof of any one of claims 1-13, wherein the first antigen is a cancer specific antigen, and the second antigen is CD3.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The bispecific antibody or antigen-binding fragment thereof of any one of claims 1-13, wherein the first antigen is CD20, and the second antigen is CD3.

### Claim 16 (depends on 15)

The bispecific antibody or antigen-binding fragment thereof of claim 15, wherein the first heavy chain variable region comprises a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 1, the second heavy chain variable region comprises a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 2, and the first and the second light chain variable regions comprise a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 3.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The bispecific antibody or antigen-binding fragment thereof of any one of claims 1-13, wherein the first antigen is a cancer specific antigen, and the second antigen is a cancer-associated antigen.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The bispecific antibody or antigen-binding fragment thereof of any one of claims 1-13, wherein the first antigen is PD-L1, and the second antigen is CD55.

### Claim 19 (depends on 18)

The bispecific antibody or antigen-binding fragment thereof of claim 18, wherein the first heavy chain variable region comprises a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 4, the second heavy chain variable region comprises a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 5, and the first and the second light chain variable regions comprise a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 6 or SEQ ID NO: 7.

### Claim 20

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, VHb, and VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining that the sequence homology between VLa and VLb is greater than 80%;
(d) designing a common light chain variable region (VLc), wherein the VLc, when it associates with VHa, maintains the affinity to the first antigen;
(e) redesigning the VHa and VHb sequences, thereby obtaining VHa′ and VHb′ to increase the difference of biochemical or biophysical characteristics between a first protein comprising two polypeptides each comprising VHa′ and two polypeptides each comprising VLc, and a second protein comprising two polypeptides each comprising VHb′ and two polypeptides each comprising VLc; and
(f) producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLc, and the two heavy chain variable regions comprise VHa′ and VHb′ respectively.

### Claim 21 (depends on 20)

The method of claim 20, wherein in step (d), the binding affinity of the VLc-VHb to the second antigen can decrease.

### Claim 22 (depends on 20)

The method of claim 20, wherein the method further comprises
(g) developing a buffer system to purify the bispecific antibody or antigen-binding fragment thereof.

### Claim 23

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, and VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining the sequence homology between VLa and VLb is less than 80%;
(d) replacing all light chain variable regions in a phage display antibody library with the VLa, and panning against the second antigen to obtain a third heavy chain variable region (VHc);
(e) redesigning the VHa and VHc sequences, thereby obtaining VHa′ and VHc′ to increase the difference of biochemical or biophysical characteristics between a first protein comprising two polypeptides each comprising VHa′ and two polypeptides each comprising VLa, and a second protein comprising two polypeptides each comprising VHc′ and two polypeptides each comprising VLa; and
(f) producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLa, and the two heavy chain variable regions comprise VHa′ and VHc′ respectively.

### Claim 24 (depends on 23)

The method of claim 23, wherein the method further comprises
(g) developing a buffer system to purify the bispecific antibody or antigen-binding fragment thereof.

### Claim 25

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, VHb, and VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining the sequence homology between VLa and VLb is less than 80%;
(d) replacing all light chain variable regions in a phage display antibody library with a plurality of light chain variable regions, wherein the light chain variables regions are at least 80%, 85%, 90%, 95%, or 99% identical to VLa or VLb;
(e) panning against the second antigen;
(f) selecting a common light chain variable region (VLc), and a third heavy chain variable region (VHc), wherein VHa-VLc binds to the first antigen with a desired affinity and VHc-VLc binds to the second antigen with a desired affinity;
(g) redesigning the VHa and VHc sequences, thereby obtaining VHa′ and VHc′ to increase the difference of biochemical or biophysical characteristics between a first protein comprising two polypeptides each comprising VHa′ and two polypeptides each comprising VLc, and a second protein comprising two polypeptides each comprising VHc′ and two polypeptides each comprising VLc; and
(h) producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLc, and the two heavy chain variable regions comprise VHa′ and VHc′ respectively.

### Claim 26 (depends on 25)

The method of claim 25, wherein in step (d), the plurality of light chain variable regions are produced by error-prone PCR.

### Claim 27 (depends on 25)

The method of claim 25, wherein the method further comprises
(i) developing a buffer system to purify the bispecific antibody or antigen-binding fragment thereof.

### Claim 28

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, VHb, and VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining the sequence homology between VLa and VLb is less than 80%;
(d) replacing all light chain variable regions in a phage display antibody library with a plurality of light chain variable regions, wherein the light chain variables regions are at least 80%, 85%, 90%, 95%, or 99% identical to VLa or VLb;
(e) panning against the second antigen;
(f) selecting a common light chain variable region (VLc), and a third heavy chain variable region (VHc), wherein VHc-VLc binds to the second antigen with a desired affinity;
(g) determining the homology between VLa and VLc is greater than 80%;
(h) designing a common light chain variable region (VLd), wherein the VLd, when it associates with VHa, maintains the affinity to the first antigen and when it associates with VHc, has desired affinity to the second antigen;
(i) optionally, redesigning the VHa and VHc sequences, thereby obtaining VHa′ and VHc′ to increase the difference of biochemical or biophysical characteristics between a first protein comprising two polypeptides each comprising VHa′ and two polypeptides each comprising VLd, and a second protein comprising two polypeptides each comprising VHc′ and two polypeptides each comprising VLd; and
(j) optionally producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLd, and the two heavy chain variable regions comprise VHa′ and VHc′ respectively.

### Claim 29

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, VHb, and VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining that the sequence homology between VLa and VLb is greater than 80%;
(d) designing a common light chain variable region (VLc), wherein the VLc, when it associates with VHa, maintains the affinity to the first antigen; and
(e) optionally, producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLc, and the two heavy chain variable regions comprise VHa and VHb respectively.

### Claim 30

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, and VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining the sequence homology between VLa and VLb is less than 80%;
(d) replacing all light chain variable regions in a phage display antibody library with the VLa, and panning against the second antigen to obtain a third heavy chain variable region (VHc); and
(e) optionally, producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLa, and the two heavy chain variable regions comprise VHa and VHc respectively.

### Claim 31

A method of making bispecific antibody or antigen-binding fragment thereof, the method comprising:
(a) selecting a first antigen and a second antigen, and identifying a first antibody or antigen-binding fragment thereof that binds to the first antigen and a second antibody or antigen-binding fragment thereof that binds to the second antigen, wherein the first antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VHa) and a first light chain variable region (VLa), and the second antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VHb) and a second light chain variable region (VLb);
(b) determining the amino acid sequence of VHa, VLa, VHb, and/or VLb;
(c) aligning the amino acid sequences of VLa and VLb and determining the sequence homology between VLa and VLb is less than 80%;
(d) replacing all light chain variable regions in a phage display antibody library with a plurality of light chain variable regions, wherein the light chain variables regions are at least 80%, 85%, 90%, 95%, or 99% identical to VLa or VLb;
(e) panning against the first and/or the second antigen;
(f) selecting a common light chain variable region (VLc), and a third heavy chain variable region (VHc), wherein VHa-VLc binds to the first antigen with a desired affinity and VHc-VLc binds to the second antigen with a desired affinity; and
(g) optionally, producing a bispecific antibody or antigen-binding fragment thereof that has two light chain variable regions and two heavy chain variable regions, wherein the two light variable regions each comprises VLc, and the two heavy chain variable regions comprise VHa and VHc respectively.

### Claim 32

An antibody or antigen-binding fragment thereof that binds to CD3 comprising:
a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence; and
a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR3 amino acid sequence,
wherein the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 22-24, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 28-30, respectively.

### Claim 33 (depends on 32)

The antibody or antigen-binding fragment thereof of claim 32, wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 22, 23, 24 respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 28, 29, 30, respectively.

### Claim 34 (depends on 32, 33)

The antibody or antigen-binding fragment thereof of any one of claims 32-33, wherein the antibody or antigen-binding fragment specifically binds to human CD3.

### Claim 35 (depends on 32, 33, 34)

The antibody or antigen-binding fragment thereof of any one of claims 32-34, wherein the antibody or antigen-binding fragment is a bispecific antibody.

### Claim 36

An antibody or antigen-binding fragment thereof that binds to PD-L1 comprising:
a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence; and
a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR3 amino acid sequence,
wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
(1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 41-43, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 53-55, respectively;
(2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 41-43, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 59-61, respectively.

### Claim 37 (depends on 36)

The antibody or antigen-binding fragment thereof of claim 36, wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 41-43 respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 59-61, respectively.

### Claim 38 (depends on 36, 37)

The antibody or antigen-binding fragment thereof of any one of claims 36-37, wherein the antibody or antigen-binding fragment specifically binds to human CD3.

### Claim 39 (depends on 36, 37, 38)

The antibody or antigen-binding fragment thereof of any one of claims 36-38, wherein the antibody or antigen-binding fragment is a bispecific antibody.

### Claim 40

An antibody or antigen-binding fragment thereof that binds to CD55 comprising:
a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence; and
a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR3 amino acid sequence,
wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
(1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 47-49, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 53-55, respectively;
(2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 47-49, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 59-61, respectively.

### Claim 41 (depends on 40)

The antibody or antigen-binding fragment thereof of claim 40, wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 47-49 respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 59-61, respectively.

### Claim 42 (depends on 40, 41)

The antibody or antigen-binding fragment thereof of any one of claims 40-41, wherein the antibody or antigen-binding fragment specifically binds to human CD3.

### Claim 43 (depends on 40, 41, 42)

The antibody or antigen-binding fragment thereof of any one of claims 40-42, wherein the antibody or antigen-binding fragment is a bispecific antibody.

### Claim 44

A nucleic acid comprising a polynucleotide encoding a polypeptide comprising:
an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 53-55, respectively, and
wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 4 binds to PD-L1, and/or when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 5 binds to CD55.

### Claim 45

A nucleic acid comprising a polynucleotide encoding a polypeptide comprising:
an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 59-61, respectively, and
wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 4 binds to PD-L1, and/or when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 5 binds to CD55.

### Claim 46 (depends on 44, 45)

The nucleic acid of any one of claims 44-45, wherein the nucleic acid encodes a bispecific antibody.

### Claim 47 (depends on 44, 45)

The nucleic acid of any one of claims 44-45, wherein the nucleic acid is cDNA.

### Claim 48 (depends on 44, 45, 46, 47)

A vector comprising one or more of the nucleic acids of any one of claims 44-47.

### Claim 49 (depends on 48)

A cell comprising the vector of claim 48.

### Claim 50 (depends on 49)

The cell of claim 49, wherein the cell is a CHO cell.

### Claim 51 (depends on 44, 45, 46, 47)

A cell comprising one or more of the nucleic acids of any one of claims 44-47.

### Claim 52

A bispecific antibody or antigen-binding fragment thereof that binds to CD20 and CD3 comprising
a first polypeptide comprising a first heavy chain variable region (VH) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1;
a second polypeptide comprising a second heavy chain variable region (VH) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2;
a third polypeptide comprising a first light chain variable region (VL) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 3;
a fourth polypeptide comprising a second light chain variable region (VL) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 3.

### Claim 53 (depends on 52)

The bispecific antibody or antigen-binding fragment thereof of claim 52, wherein
the first heavy chain variable region (VH) comprises SEQ ID NO: 1;
the second heavy chain variable region (VH) comprise SEQ ID NO: 2;
the first light chain variable region (VL) comprise SEQ ID NO: 3; and
the second light chain variable region (VL) comprises SEQ ID NO: 3.

### Claim 54 (depends on 52)

The bispecific antibody or antigen-binding fragment thereof of claim 52, wherein
the first polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 40.

### Claim 55 (depends on 52)

The bispecific antibody or antigen-binding fragment thereof of claim 52, wherein
the first polypeptide comprises an amino acid sequence that is set forth in SEQ ID NO: 35; and
the second polypeptide comprises an amino acid sequence that is set forth in SEQ ID NO: 38.

### Claim 56

A bispecific antibody or antigen-binding fragment thereof that binds to PD-L1 and CD55 comprising
a first polypeptide comprising a first heavy chain variable region (VH) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 4;
a second polypeptide comprising a second heavy chain variable region (VH) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5;
a third polypeptide comprising a first light chain variable region (VL) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7;
a fourth polypeptide comprising a second light chain variable region (VL) comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7.

### Claim 57 (depends on 56)

The bispecific antibody or antigen-binding fragment thereof of claim 56, wherein
the first heavy chain variable region (VH) comprises SEQ ID NO: 4;
the second heavy chain variable region (VH) comprise SEQ ID NO: 5;
the first light chain variable region (VL) comprise SEQ ID NO: 7; and
the second light chain variable region (VL) comprises SEQ ID NO: 7.

### Claim 58 (depends on 56)

The bispecific antibody or antigen-binding fragment thereof of claim 56, wherein
the first polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 65;
the second polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 66;
the third polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 67 or 68; and
the fourth polypeptide comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 67 or 68.

### Claim 59 (depends on 56)

The bispecific antibody or antigen-binding fragment thereof of claim 56, wherein
the first polypeptide comprises an amino acid sequence that is set forth in SEQ ID NO: 65;
the second polypeptide comprises an amino acid sequence that is set forth in SEQ ID NO: 66;
the third polypeptide comprises an amino acid sequence that is set forth in SEQ ID NO: 68; and
the fourth polypeptide comprises an amino acid sequence that is set forth in SEQ ID NO: 68.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1-19, 32-43, and 52-59 covalently bound to a therapeutic agent.

### Claim 61 (depends on 60)

The antibody drug conjugate of claim 60, wherein the therapeutic agent is a cytotoxic or cytostatic agent.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 60, 61)

A method of treating a subject having cancer, the method comprising administering a therapeutically effective amount of a composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-19, 32-43, and 52-59, or the antibody-drug conjugate of claim 60 or 61, to the subject.

### Claim 63 (depends on 62)

The method of claim 62, wherein the subject has a solid tumor.

### Claim 64 (depends on 62)

The method of claim 62, wherein the cancer is melanoma, pancreatic carcinoma, or a hematological malignancy.

### Claim 65 (depends on 62)

The method of claim 62, wherein the cancer is Non-Hodgkin's lymphoma, lymphoma, or chronic lymphocytic leukemia.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 60, 61)

A method of decreasing the rate of tumor growth, the method comprising contacting a tumor cell with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof of any one of claims 1-19, 32-43, and 52-59, or the antibody-drug conjugate of claim 60 or 61, to the subject.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 60, 61)

A method of killing a tumor cell, the method comprising contacting a tumor cell with an effective amount of a composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-19, 32-43, and 52-59, or the antibody-drug conjugate of claim 60 or 61, to the subject.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-19, 32-43, and 52-59, and a pharmaceutically acceptable carrier.

### Claim 69 (depends on 60, 61)

A pharmaceutical composition comprising the antibody drug conjugate of claim 60 or 61, and a pharmaceutically acceptable carrier.
